Cargando…
Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation
Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876681/ https://www.ncbi.nlm.nih.gov/pubmed/24416593 http://dx.doi.org/10.1155/2013/565824 |
_version_ | 1782297533432725504 |
---|---|
author | Pitombeira, Beatriz Stela Paz, Alessandra Pezzi, Annelise Amorin, Bruna Valim, Vanessa Laureano, Alvaro Wieck, Andrea Rigoni, Lisandra Ottoni, Érica Fisher, Gustavo Daudt, Liane Silla, Lucia |
author_facet | Pitombeira, Beatriz Stela Paz, Alessandra Pezzi, Annelise Amorin, Bruna Valim, Vanessa Laureano, Alvaro Wieck, Andrea Rigoni, Lisandra Ottoni, Érica Fisher, Gustavo Daudt, Liane Silla, Lucia |
author_sort | Pitombeira, Beatriz Stela |
collection | PubMed |
description | Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P < 0.001), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P = 0.001). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil. |
format | Online Article Text |
id | pubmed-3876681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38766812014-01-12 Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation Pitombeira, Beatriz Stela Paz, Alessandra Pezzi, Annelise Amorin, Bruna Valim, Vanessa Laureano, Alvaro Wieck, Andrea Rigoni, Lisandra Ottoni, Érica Fisher, Gustavo Daudt, Liane Silla, Lucia Bone Marrow Res Research Article Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P < 0.001), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P = 0.001). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil. Hindawi Publishing Corporation 2013 2013-12-12 /pmc/articles/PMC3876681/ /pubmed/24416593 http://dx.doi.org/10.1155/2013/565824 Text en Copyright © 2013 Beatriz Stela Pitombeira et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Pitombeira, Beatriz Stela Paz, Alessandra Pezzi, Annelise Amorin, Bruna Valim, Vanessa Laureano, Alvaro Wieck, Andrea Rigoni, Lisandra Ottoni, Érica Fisher, Gustavo Daudt, Liane Silla, Lucia Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title | Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title_full | Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title_fullStr | Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title_short | Validation of the EBMT Risk Score for South Brazilian Patients
Submitted to Allogeneic Hematopoietic Stem Cell Transplantation |
title_sort | validation of the ebmt risk score for south brazilian patients
submitted to allogeneic hematopoietic stem cell transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876681/ https://www.ncbi.nlm.nih.gov/pubmed/24416593 http://dx.doi.org/10.1155/2013/565824 |
work_keys_str_mv | AT pitombeirabeatrizstela validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT pazalessandra validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT pezziannelise validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT amorinbruna validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT valimvanessa validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT laureanoalvaro validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT wieckandrea validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT rigonilisandra validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT ottonierica validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT fishergustavo validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT daudtliane validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation AT sillalucia validationoftheebmtriskscoreforsouthbrazilianpatientssubmittedtoallogeneichematopoieticstemcelltransplantation |